| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/20-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | HET; ITM; BWR1A; IMPT1; TSSC5; ORCTL2; BWSCR1A; SLC22A1L; p45-BWR1A |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human SLC22A18 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇涉及SLC22A18抗体的参考文献及其摘要概括：
---
1. **文献名称**: *"SLC22A18 downregulation in hepatocellular carcinoma contributes to tumorigenesis by regulating proliferation and apoptosis"*
**作者**: Zhang Y et al.
**摘要**: 研究通过Western blot和免疫组化(使用SLC22A18抗体)发现，SLC22A18在肝癌组织中表达显著下调，其低表达与细胞增殖增强、凋亡抑制相关，提示其作为肝癌潜在抑癌基因的作用。
---
2. **文献名称**: *"Epigenetic silencing of SLC22A18 promotes lung adenocarcinoma progression via mTOR pathway activation"*
**作者**: Li H et al.
**摘要**: 研究利用SLC22A18特异性抗体检测肺癌组织中的蛋白表达，发现启动子甲基化导致SLC22A18表达缺失，进而激活mTOR通路促进肿瘤生长，提示其表观遗传调控在肺癌中的重要性。
---
3. **文献名称**: *"SLC22A18 as a biomarker for chemoresistance in colorectal cancer: Insights from antibody-based proteomic analysis"*
**作者**: Wang X et al.
**摘要**: 通过免疫荧光和流式细胞术(使用抗SLC22A18抗体)，研究发现SLC22A18低表达与结直肠癌患者化疗耐药性显著相关，可能通过调节药物转运蛋白功能影响治疗效果。
---
注：以上文献名为示例性概括，实际文献需通过PubMed/Google Scholar以关键词"SLC22A18 antibody"或结合具体疾病名称检索确认。
The SLC22A18 antibody targets the protein encoded by the *SLC22A18* gene, a member of the solute carrier family 22 (SLC22) involved in transmembrane transport of organic ions and metabolites. Located on chromosome 11p15.5. this gene resides in a genomic region associated with imprinting disorders and tumorigenesis. SLC22A18. also known as ORCTL2 or BWR1A, is proposed to function as a tumor suppressor, with roles in regulating cell proliferation, apoptosis, and metabolic processes. Epigenetic silencing or loss of heterozygosity at this locus has been linked to cancers, including pediatric tumors (e.g., Wilms' tumor) and adult carcinomas.
The SLC22A18 antibody is widely used in research to study protein expression, subcellular localization (e.g., plasma membrane or cytoplasmic distribution), and its interaction with signaling pathways in both normal and diseased tissues. It serves as a critical tool in immunohistochemistry (IHC), Western blotting, and immunofluorescence (IF) to explore tissue-specific expression patterns and dysregulation in malignancies. Studies utilizing this antibody have also investigated its potential role in drug transport and metabolic diseases. Despite its importance, challenges remain in fully elucidating its substrate specificity and regulatory mechanisms. Ongoing research aims to clarify its diagnostic or therapeutic relevance in oncology and metabolic disorders.
×
